Home › Funds › Catalio Capital Management, LP › ASND

Catalio Capital Management, LP position in ASND

ASCENDIS PHARMA A/S · Health Care

Catalio Capital Management, LP reported holding 31,759 shares of ASND (ASCENDIS PHARMA A/S) in its Q2 2026 13F filing — a position valued at US$8.5M, representing 1.59% of its reported portfolio and ranking #24 among its reported holdings. Catalio Capital Management, LP has disclosed ASND holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)31.76K sh
Reported value held$8.47M
Portfolio Weight1.59%
First reportedQ4 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's ASND position evolved

Catalio Capital Management, LP first disclosed a stake in ASND in Q4 2024 at 215,587 shares (US$29.7M). The position peaked in Q2 2025 at 179,926 shares, worth US$31.1M. Across 7 filings, Catalio Capital Management, LP increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 31,759 shares valued at US$8.5M — a reduction of -97,352 shares quarter over quarter.. Notable position changes include a 75% trim in Q2 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 215.59K $29.68M New
Q1 2025 195.52K $30.47M Reduce
Q2 2025 179.93K $31.06M Reduce
Q3 2025 144.95K $28.82M Reduce
Q4 2025 119.27K $25.43M Reduce
Q1 2026 129.11K $29.53M Add
Q2 2026 31.76K $8.47M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 43 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has Catalio Capital Management, LP held ASND?

Catalio Capital Management, LP has disclosed ASND holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Catalio Capital Management, LP's current position in ASND?

As of Q2 2026, Catalio Capital Management, LP holds 31.76K shares of ASND (ASCENDIS PHARMA A/S), valued at $8.47M, representing 1.59% of its reported portfolio and ranking #24.

Has Catalio Capital Management, LP been buying or selling ASND?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP reduced its position in ASND. The position peaked in Q2 2025 at 179.93K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.